Indore-based manufacturer and exporter of active pharmaceutical ingredients (APIs), intermediates and finished formulations, expanding into fermentation-based products
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 5 | 5 | 10 | 12 | 13 | 13 | 13 | 13 |
| Reserves | 30 | 35 | 37 | 84 | 112 | 121 | 125 | 128 |
| Borrowings | 4 | 4 | 4 | 6 | 6 | 5 | 4 | 6 |
| Other Liabilities | 12 | 14 | 22 | 21 | 28 | 24 | 29 | 25 |
| Total Liabilities | 52 | 58 | 74 | 123 | 159 | 163 | 171 | 172 |
| AssetsFixed Assets | 6 | 7 | 7 | 8 | 14 | 18 | 19 | 20 |
| CWIP | 2 | 2 | 2 | 4 | 6 | 15 | 17 | 17 |
| Investments | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 44 | 49 | 65 | 111 | 137 | 131 | 135 | 135 |
| Total Assets | 52 | 58 | 74 | 123 | 159 | 163 | 171 | 172 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 2 | 5 | 5 | -2 | 0 | 10 | 4 | 10 |
| Cash from Investing | -1 | -2 | -1 | 0 | -34 | -7 | -16 | -7 |
| Cash from Financing | -2 | -1 | -2 | -1 | 36 | 16 | -5 | -4 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 1 | 4 | 3 | -3 | -4 | 0 | -12 | 3 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (2.7×) and current (3.5×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -12.4% growth and a 3× exit, ₹29 only delivers your return if you pay ₹5. The price is currently baking in 21% growth.
EPS grows -12.4%/yr for 5 years, then fades to 6% over 2, exits at 3×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -12.4% | 7.20 |
| FY28 | -12.4% | 6.31 |
| FY29 | -12.4% | 5.53 |
| FY30 | -12.4% | 4.84 |
| FY31 | -12.4% | 4.24 |
| FY32 | -3.2% ·fade | 4.10 |
| FY33 | 6.0% ·fade | 4.35 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.